We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Development of a novel filtered-based pharmacophore for the identification of human equilibrative nucleoside transporter 1 inhibitors.
- Authors
Ramadan, Azza; Hasan, Shaima; Jamal, Sedra; Moumen, Ismail; Atatreh, Noor; Ghattas, Mohammad A
- Abstract
The human equilibrative nucleoside transporters (hENTs) are important proteins that allow nucleosides and nucleobases permeation into the cell. hENT 1 is a promising target against heart and Huntington’s diseases as its inhibition mediates cardiac- and neural protection effects, respectively. However, the current hENT1 inhibitors have significant off-target effects and poor pharmacological profile, hence there is need for new novel inhibitors. Therefore, we developed a computational protocol that identified and selected inhibitors of hENT1 in an efficient and specific manner. First, several pharmacophores were created using a set of known inhibitors. Consequently, the best inhibitor pharmacophore exhibited as high selectivity and specificity rates as 92% and 88%, respectively. Furthermore, another pharmacophore was validated for the oppositely acting type of the hENT1 molecules (i.e. permeants) to act as an extra refinement step in our search for hENT1 inhibitors. Interestingly, employing the inhibitor pharmacophore as a filter-in along with the permeant pharmacophore as a filter-out resulted in up to twofold enhancement of docking-based virtual screening results of hENT1 inhibitors. This in silico approach can prove very useful in the development of new cardio- and neuroprotective hENT1 inhibitors.
- Subjects
NUCLEOSIDE transport proteins; HUNTINGTON disease; ATP-binding cassette transporters; BASE pairs; NUCLEOSIDES
- Publication
Jordan Journal of Pharmaceutical Sciences, 2021, Vol 14, Issue 3, p293
- ISSN
1995-7157
- Publication type
Article